Neomycin and Polymyxin B Sulfates and Bacitracin Zinc Ointment
If you find any inaccurate information, please let us know by providing your feedback here
This article is compiled based on the United States Pharmacopeia (USP) – 2025 Edition
Issued and maintained by the United States Pharmacopeial Convention (USP)
Neomycin and Polymyxin B Sulfates and Bacitracin Zinc Ointment contains the equivalent of not less than 90.0 percent and not more than 130.0 percent of the labeled amounts of neomycin, polymyxin B, and bacitracin. It may contain a suitable local anesthetic.
Packaging and storage-Preserve in well-closed containers, preferably at controlled room temperature.
USP REFERENCE STANDARDS (11)-
USP Bacitracin Zinc RS
USP Neomycin Sulfate RS
USP Polymyxin B Sulfate RS
THIN-LAYER CHROMATOGRAPHIC IDENTIFICATION TEST (201BNP): meets the requirements.
MINIMUM FILL (755): meets the requirements.
WATER DETERMINATION, Method | (921): not more than 0.5%, 20 mL of a mixture of toluene and methanol (7:3) being used in place of methanol in the titration vessel.
Assay for neomycin, Assay for polymyxin B, and Assay for bacitracin-Proceed with Ointment as directed in the Assay for neomycin, in the Assay for polymyxin B, and in the Assay for bacitracin under Neomycin and Polymyxin B Sulfates and Bacitracin Zinc Ophthalmic Ointment.
